MCID: OVR060
MIFTS: 46

Ovary Epithelial Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovary Epithelial Cancer

MalaCards integrated aliases for Ovary Epithelial Cancer:

Name: Ovary Epithelial Cancer 12 15
Ovarian Surface Epithelial-Stromal Tumor 12
Epithelial Tumor of Ovary 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2152
NCIt 51 C4381
UMLS 74 C0341823

Summaries for Ovary Epithelial Cancer

Disease Ontology : 12 An ovarian cancer that is derives from ovarian surface epithelium.

MalaCards based summary : Ovary Epithelial Cancer, also known as ovarian surface epithelial-stromal tumor, is related to krukenberg carcinoma and ovarian mucinous neoplasm. An important gene associated with Ovary Epithelial Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Carboplatin and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and brain, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Ovary Epithelial Cancer

Diseases related to Ovary Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 krukenberg carcinoma 32.6 HNF1B KRT7
2 ovarian mucinous neoplasm 31.9 CEACAM5 KRT7 WT1
3 malignant ovarian surface epithelial-stromal neoplasm 29.4 ACSBG1 AKT1 ARID1A BRCA1 BRCA2 CDH1
4 ovarian squamous cell neoplasm 11.1
5 ovarian endometrial cancer 11.1
6 ovarian papillary neoplasm 11.1
7 breast reconstruction 10.6 BRCA1 BRCA2
8 nosophobia 10.6 BRCA1 BRCA2
9 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
10 cancerophobia 10.6 BRCA1 BRCA2
11 breast medullary carcinoma 10.6 BRCA1 ERBB2
12 cerebral convexity meningioma 10.6 CDH1 TP53
13 adult hepatocellular carcinoma 10.6 PIK3CA TP53
14 intravascular papillary endothelial hyperplasia 10.6 SERPINA3 VEGFA
15 cerebellar angioblastoma 10.6 TP53 WT1
16 breast cystic hypersecretory carcinoma 10.6 CDH1 ERBB2
17 bladder benign neoplasm 10.6 KRT7 PAX8
18 benign mesothelioma 10.5 KRT7 WT1
19 nephrogenic adenoma of urinary bladder 10.5 KRT7 PAX8
20 li-fraumeni syndrome 10.5 BRCA1 BRCA2 TP53
21 mutagen sensitivity 10.5 BRCA1 BRCA2 TP53
22 intracranial chondrosarcoma 10.5 CEACAM5 TP53
23 hereditary breast ovarian cancer syndrome 10.5 BRCA1 BRCA2 TP53
24 intracystic papillary adenoma 10.5 CEACAM5 ERBB2
25 gallbladder squamous cell carcinoma 10.5 CEACAM5 ERBB2
26 adenosquamous gallbladder carcinoma 10.5 CEACAM5 SERPINA3
27 bilateral breast cancer 10.5 BRCA1 BRCA2 ERBB2
28 prostate adenoid cystic carcinoma 10.5 HRAS PIK3CA
29 mucinous adenofibroma 10.5 CEACAM5 KRT7
30 acinar cell carcinoma 10.5 BRCA2 KRT7 TP53
31 anus adenocarcinoma 10.5 CEACAM5 KRT7
32 sweat gland cancer 10.5 ERBB2 KRT7 TP53
33 cutaneous mucoepidermoid carcinoma 10.5 CEACAM5 KRT7
34 anal gland adenocarcinoma 10.5 CEACAM5 KRT7
35 granulosa cell tumor of the ovary 10.5 ERBB2 KRT7 TP53
36 hidradenocarcinoma 10.5 ERBB2 KRT7 TP53
37 esophageal adenosquamous carcinoma 10.5 CDH1 CEACAM5
38 pancreatic ductal carcinoma 10.5 KRT7 TP53 VEGFA
39 laryngeal squamous cell carcinoma 10.5 CDH1 TP53 VEGFA
40 dysgerminoma of ovary 10.5 BRCA1 BRCA2 WT1
41 thymus cancer 10.5 KRT7 PAX8 TP53
42 prostate disease 10.5 AKT1 SERPINA3 TP53
43 oropharynx cancer 10.5 CDH1 KRT7 TP53
44 nervous system cancer 10.5 AKT1 TP53 VEGFA
45 central nervous system cancer 10.5 AKT1 TP53 VEGFA
46 dysgerminoma 10.5 BRCA1 KRT7 WT1
47 tuberculous salpingitis 10.5 BRCA1 BRCA2 ERBB2
48 grade iii astrocytoma 10.5 MMP2 TP53 VEGFA
49 retinal hemangioblastoma 10.4 PAX8 SERPINA3 VEGFA
50 urachal adenocarcinoma 10.4 CEACAM5 KRAS

Graphical network of the top 20 diseases related to Ovary Epithelial Cancer:



Diseases related to Ovary Epithelial Cancer

Symptoms & Phenotypes for Ovary Epithelial Cancer

GenomeRNAi Phenotypes related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

27 (show all 48)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.56 KRAS
3 Decreased viability GR00221-A-1 10.56 AKT1 HRAS KRAS PIK3CA CDH1
4 Decreased viability GR00221-A-2 10.56 AKT1 BRCA1 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.56 AKT1 BRCA1 HRAS
6 Decreased viability GR00221-A-4 10.56 AKT1 PIK3CA
7 Decreased viability GR00301-A 10.56 BRCA1 KRAS CDH1
8 Decreased viability GR00381-A-1 10.56 KRAS
9 Decreased viability GR00402-S-2 10.56 AKT1 BRCA1 HRAS KRAS PIK3CA CDH1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.99 WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.99 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.99 BRCA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.99 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.99 BRCA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.99 BRCA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.99 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.99 HNF1B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.99 PAX8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.99 ARID1A BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.99 ARID1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.99 HNF1B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.99 HRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.99 BRCA1 HNF1B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.99 ARID1A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.99 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.99 HRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.99 HNF1B WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.99 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.99 PAX8
30 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.99 PAX8
31 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.99 WT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.99 WT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.99 PAX8
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.99 ARID1A BRCA1 HNF1B HRAS PAX8 WT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.99 WT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.99 HNF1B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.99 HNF1B
38 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.99 BRCA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.99 BRCA1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.99 ARID1A
41 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.99 HNF1B PAX8
42 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.99 HNF1B
43 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.99 HNF1B
44 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.99 PAX8
45 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.99 HRAS
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.99 WT1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.99 PAX8
48 Decreased viability in esophageal squamous lineage GR00235-A 9.77 ARID1A BRCA1 BRCA2 CDH1 ERBB2 HNF1B

MGI Mouse Phenotypes related to Ovary Epithelial Cancer:

47 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ACSBG1 AKT1 ARID1A BRCA1 BRCA2 CDH1
2 endocrine/exocrine gland MP:0005379 10.43 ACSBG1 AKT1 ARID1A BRCA1 BRCA2 CDH1
3 growth/size/body region MP:0005378 10.42 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
4 cardiovascular system MP:0005385 10.41 AKT1 ARID1A BRCA1 CDH1 ERBB2 HRAS
5 cellular MP:0005384 10.4 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
6 embryo MP:0005380 10.38 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
7 mortality/aging MP:0010768 10.35 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
8 immune system MP:0005387 10.3 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
9 neoplasm MP:0002006 10.25 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
10 integument MP:0010771 10.21 AKT1 BRCA1 BRCA2 CDH1 ERBB2 HRAS
11 muscle MP:0005369 10.2 AKT1 ARID1A BRCA1 ERBB2 HNF1B KRAS
12 craniofacial MP:0005382 10.19 ARID1A ERBB2 HRAS KRAS MMP2 PAX8
13 digestive/alimentary MP:0005381 10.18 BRCA1 BRCA2 CDH1 ERBB2 HRAS KRAS
14 nervous system MP:0003631 10.18 AKT1 ARID1A BRCA1 BRCA2 ERBB2 HRAS
15 normal MP:0002873 10.13 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
16 no phenotypic analysis MP:0003012 10.07 ARID1A CDH1 ESS2 HRAS KRAS PAX8
17 limbs/digits/tail MP:0005371 10.04 BRCA1 BRCA2 ERBB2 KRAS PAX8 TP53
18 reproductive system MP:0005389 9.97 ACSBG1 AKT1 ARID1A BRCA1 BRCA2 CDH1
19 renal/urinary system MP:0005367 9.91 BRCA1 HNF1B HRAS KRAS KRT7 PAX8
20 respiratory system MP:0005388 9.61 AKT1 BRCA1 ERBB2 HRAS KRAS MMP2
21 skeleton MP:0005390 9.4 AKT1 ARID1A BRCA1 BRCA2 ERBB2 HRAS

Drugs & Therapeutics for Ovary Epithelial Cancer

Drugs for Ovary Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
2
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
3
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
4
Indinavir Approved Phase 2 150378-17-9 5362440
5
Belinostat Approved, Investigational Phase 2 866323-14-0
6
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
7
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
8
Fondaparinux Approved, Investigational Phase 2 104993-28-4
9
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
10
Amifostine Approved, Investigational Phase 2,Phase 1 20537-88-6 2141
11
Ifosfamide Approved Phase 2 3778-73-2 3690
12
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
13
Etoposide Approved Phase 2 33419-42-0 36462
14
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
15
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
16
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
17
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
20 Squalamine Investigational Phase 2 148717-90-2
21
Veliparib Investigational Phase 2 912444-00-9 11960529
22
Oblimersen Experimental, Investigational Phase 1, Phase 2 190977-41-4
23
Doxil Approved June 1999 Phase 2 31703
24 Angiogenesis Inhibitors Phase 2,Phase 1
25 Angiogenesis Modulating Agents Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 2
27 Anti-Infective Agents Phase 2,Phase 1
28 Protective Agents Phase 2,Phase 1
29 Anti-HIV Agents Phase 2
30 Anti-Retroviral Agents Phase 2
31 Liver Extracts Phase 2,Phase 1
32
protease inhibitors Phase 2,Phase 1
33 Antiviral Agents Phase 2,Phase 1
34 Cytochrome P-450 CYP3A Inhibitors Phase 2
35 HIV Protease Inhibitors Phase 2,Phase 1
36 Cytochrome P-450 Enzyme Inhibitors Phase 2
37 Cola Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 2,Phase 1
39 Imatinib Mesylate Phase 2 220127-57-1 123596
40 Histone Deacetylase Inhibitors Phase 2,Phase 1
41 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
42 Mitogens Phase 2,Phase 1
43 Antibodies Phase 2,Phase 1
44 Immunologic Factors Phase 2,Phase 1
45 Endothelial Growth Factors Phase 2,Phase 1
46 Antibodies, Monoclonal Phase 2,Phase 1
47 Antineoplastic Agents, Immunological Phase 2,Phase 1
48 Immunoglobulin G Phase 2,Phase 1
49 Immunoglobulins Phase 2,Phase 1
50 Fibrinolytic Agents Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
2 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
3 Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor Completed NCT00039585 Phase 2 imatinib mesylate
4 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed NCT00301756 Phase 2 Belinostat
5 Gefitinib in Treating Patients With Cervical Cancer Completed NCT00049556 Phase 2 gefitinib
6 Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01540565 Phase 2 Veliparib
7 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
8 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
9 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
11 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
12 Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients Recruiting NCT03509246 Phase 2 Pegylated liposomal doxorubicin plus Bortezomib
13 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
14 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
15 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
16 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
17 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
18 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
19 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
20 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
21 LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Completed NCT00005858 Phase 1
22 Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Completed NCT00005807 Phase 1 BMS-247550
23 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
24 Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Recruiting NCT02520115 Phase 1 Dexamethasone;Valproic Acid
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
26 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer Completed NCT01096394
27 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
28 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
29 Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer Completed NCT00383279 Not Applicable
30 Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer Completed NCT00003763 Not Applicable
31 Inherited Susceptible Genes Among Epithelial Ovarian Cancer Recruiting NCT03015376
32 Sub-type Specific Genomic Mutations in sBOTs Active, not recruiting NCT03883542

Search NIH Clinical Center for Ovary Epithelial Cancer

Genetic Tests for Ovary Epithelial Cancer

Anatomical Context for Ovary Epithelial Cancer

MalaCards organs/tissues related to Ovary Epithelial Cancer:

42
Ovary, Breast, Brain, Liver, Lung, Colon, Endothelial

Publications for Ovary Epithelial Cancer

Variations for Ovary Epithelial Cancer

Expression for Ovary Epithelial Cancer

Search GEO for disease gene expression data for Ovary Epithelial Cancer.

Pathways for Ovary Epithelial Cancer

Pathways related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 AKT1 BRCA1 BRCA2 ERBB2 HRAS KRAS
2
Show member pathways
13.62 AKT1 BRCA1 CDH1 ERBB2 HNF1B HRAS
3
Show member pathways
13.58 AKT1 ERBB2 HNF1B HRAS KRAS KRT7
4
Show member pathways
13.46 AKT1 ERBB2 HRAS KRAS MMP2 PIK3CA
5
Show member pathways
13.41 AKT1 CEACAM5 HRAS KRAS PIK3CA SERPINA3
6
Show member pathways
13.12 AKT1 HRAS KRAS MMP2 PIK3CA VEGFA
7
Show member pathways
13.1 AKT1 CDH1 HRAS KRAS TP53 VEGFA
8
Show member pathways
13.05 AKT1 HRAS KRAS PIK3CA TP53 VEGFA
9
Show member pathways
13.05 AKT1 BRCA1 ERBB2 HRAS KRAS PIK3CA
10
Show member pathways
13.04 AKT1 HRAS KRAS PIK3CA TP53 VEGFA
11
Show member pathways
13.02 AKT1 BRCA1 BRCA2 HRAS KRAS TP53
12
Show member pathways
13 AKT1 ERBB2 HRAS KRAS PIK3CA VEGFA
13
Show member pathways
13 AKT1 ERBB2 HRAS KRAS PIK3CA VEGFA
14
Show member pathways
12.89 AKT1 HRAS KRAS PIK3CA TP53
15 12.86 AKT1 ERBB2 HRAS KRAS TP53 VEGFA
16
Show member pathways
12.85 AKT1 BRCA2 CDH1 ERBB2 HRAS KRAS
17
Show member pathways
12.82 AKT1 CDH1 HRAS KRAS PIK3CA VEGFA
18
Show member pathways
12.82 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
19
Show member pathways
12.78 AKT1 CDH1 ERBB2 HRAS KRAS PIK3CA
20
Show member pathways
12.76 AKT1 HRAS KRAS MMP2 PIK3CA VEGFA
21
Show member pathways
12.69 AKT1 HRAS KRAS PIK3CA VEGFA
22
Show member pathways
12.69 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
23
Show member pathways
12.65 AKT1 ERBB2 HRAS KRAS MMP2 PIK3CA
24
Show member pathways
12.62 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
25
Show member pathways
12.59 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
26
Show member pathways
12.58 AKT1 ERBB2 HRAS KRAS PIK3CA
27 12.56 BRCA1 ERBB2 HRAS KRAS PIK3CA TP53
28
Show member pathways
12.54 AKT1 HRAS KRAS PIK3CA
29
Show member pathways
12.54 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
30
Show member pathways
12.52 AKT1 HRAS KRAS PIK3CA VEGFA
31
Show member pathways
12.51 AKT1 HRAS PIK3CA TP53
32
Show member pathways
12.5 AKT1 HRAS KRAS PIK3CA
33
Show member pathways
12.48 AKT1 HRAS KRAS PIK3CA
34
Show member pathways
12.48 CDH1 ERBB2 HRAS KRAS PIK3CA
35
Show member pathways
12.48 AKT1 BRCA1 HRAS KRAS PIK3CA VEGFA
36
Show member pathways
12.47 AKT1 HRAS PIK3CA TP53
37
Show member pathways
12.46 AKT1 HRAS KRAS PIK3CA
38 12.45 AKT1 HRAS KRAS PIK3CA TP53
39 12.42 AKT1 BRCA2 CDH1 ERBB2 HRAS KRAS
40
Show member pathways
12.41 AKT1 ERBB2 HRAS PIK3CA
41
Show member pathways
12.41 AKT1 HRAS KRAS PIK3CA
42
Show member pathways
12.39 AKT1 HRAS PIK3CA TP53
43
Show member pathways
12.39 AKT1 ERBB2 HRAS KRAS PIK3CA
44 12.38 HRAS KRAS PIK3CA TP53
45
Show member pathways
12.35 AKT1 HRAS KRAS TP53 VEGFA
46
Show member pathways
12.33 CEACAM5 HRAS KRAS PIK3CA
47
Show member pathways
12.33 AKT1 HRAS KRAS VEGFA
48
Show member pathways
12.31 AKT1 HRAS KRAS PIK3CA
49
Show member pathways
12.3 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
50
Show member pathways
12.29 AKT1 HRAS KRAS PIK3CA

GO Terms for Ovary Epithelial Cancer

Cellular components related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 ACSBG1 AKT1 BRCA1 BRCA2 CDH1 ERBB2
2 nucleus GO:0005634 9.47 AKT1 ARID1A BRCA1 BRCA2 ERBB2 ESS2

Biological processes related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 BRCA2 ERBB2 HRAS TP53
2 negative regulation of apoptotic process GO:0043066 9.85 AKT1 CEACAM5 HNF1B TP53 VEGFA WT1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 PIK3CA VEGFA
4 liver development GO:0001889 9.8 HNF1B KRAS PIK3CA
5 positive regulation of protein phosphorylation GO:0001934 9.8 AKT1 ERBB2 HRAS KRAS VEGFA
6 Ras protein signal transduction GO:0007265 9.79 HRAS KRAS TP53
7 kidney development GO:0001822 9.78 HNF1B PAX8 VEGFA WT1
8 positive regulation of epithelial cell proliferation GO:0050679 9.77 ERBB2 HRAS VEGFA
9 phosphatidylinositol 3-kinase signaling GO:0014065 9.67 AKT1 ERBB2 PIK3CA
10 cell aging GO:0007569 9.63 BRCA2 HRAS TP53
11 cytokine-mediated signaling pathway GO:0019221 9.63 AKT1 KRAS MMP2 PIK3CA TP53 VEGFA
12 anoikis GO:0043276 9.62 AKT1 PIK3CA
13 positive regulation of MAP kinase activity GO:0043406 9.62 ERBB2 HRAS KRAS VEGFA
14 cellular response to gonadotropin stimulus GO:0071371 9.61 PAX8 WT1
15 positive regulation of transcription, DNA-templated GO:0045893 9.61 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
16 mesonephric tubule development GO:0072164 9.59 HNF1B PAX8
17 response to isolation stress GO:0035900 9.58 HRAS KRAS
18 pronephros development GO:0048793 9.58 HNF1B PAX8
19 cellular response to indole-3-methanol GO:0071681 9.56 BRCA1 CDH1
20 metanephric epithelium development GO:0072207 9.55 PAX8 WT1
21 metanephric S-shaped body morphogenesis GO:0072284 9.54 PAX8 WT1
22 chordate embryonic development GO:0043009 9.52 BRCA1 BRCA2
23 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.51 HNF1B PAX8
24 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 BRCA1 BRCA2 TP53
25 positive regulation of gene expression GO:0010628 9.28 AKT1 BRCA1 ERBB2 HNF1B HRAS KRAS
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 AKT1 BRCA1 HNF1B HRAS PAX8 TP53
27 nervous system development GO:0007399 10.02 AKT1 ARID1A ERBB2 ESS2 VEGFA

Molecular functions related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.65 ACSBG1 AKT1 ERBB2 HRAS KRAS
2 transcription regulatory region DNA binding GO:0044212 9.35 BRCA1 HNF1B PAX8 TP53 WT1
3 identical protein binding GO:0042802 9.23 AKT1 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
4 protein binding GO:0005515 10.11 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2

Sources for Ovary Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....